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In this work, solid lipid nanoparticles (SLN) were used to encapsulate perillyl alcohol (PA), a volatile 
monoterpene with proven anticancer activity. Encapsulation of PA into SLN (SLN-PA) is expected to 
promote controlled release, increase PA bioavailability, and impair the volatility of the monoterpene. 
SLN-PA prepared by high-shear homogenization showed average particle diameter around 254 nm, 
polydispersity index ~ 0.35, zeta potential ~ -14.7 mV, and encapsulation efficiency 84.6%. Scanning 
electron microscope analysis revealed a decrease in crystallinity, suggesting the encapsulation of PA in 
the SLN, confirming the spherical shape and the loading of the monoterpene in the SLN. In vitro cyto-
toxicity assays against murine fibroblasts (L929) showed that SLN-PA in both treated doses did not 
induce any cytotoxicity on non-tumoral cells. In vivo antitumor effect of the SLN-PA was evaluated in 
sarcoma 180-transplanted mice. The in vivo results demonstrated a significant tumor inhibition rate of 
51.76 and 54.49% via intraperitoneal application of SLN-PA at doses of 100 and 200 mg/kg/day (p < 
0.05), respective when compared to the negative control (dimethyl sulfoxide). Adverse side effects of 
SLN-PA were not noticed in the liver, the kidney, or spleen tissue. The developed SLN-PA can be 
considered as a safe approach for site-specific antitumor effect in vivo, reinterpreting new nanoparti-
cles-based cancer therapy. 
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1 Introduction 
Current cancer treatment options include sur-
gery, chemotherapy, and radiation therapy [1-
4]. Even with these existing treatment modali-
ties, cancer still causes more deaths than all cor-
onary heart diseases or strokes, with increasing 
world estimates for the coming decades [5, 6]. 
Consequentially, the use of naturally derived 
substances for cancer treatment has been gain-
ing attention in recent years for the develop-
ment of new therapeutic approaches.  
Monoterpenes are being widely studied 
among the natural compounds because of their 
known pharmacological properties, such as an-
tifungal, antibacterial, antioxidant, anticancer, 
antiarrhythmic, anti-aggregating, local anes-
thetic, antinociceptive, anti-inflammatory, anti-
histaminic, and anti-spasmodic activities [7-
10]. Perillyl alcohol (PA) is a phenolic mono-
terpene present in several essential oils. In con-
trast, several studies highlight antiproliferative 
activity for in vitro human tumor cell lines, its 
antitumor activity in vivo, and it can be found 
in phase II clinical studies for the treatment of 
glioblastomas [11-13]. However, the use of PA 
in the pharmaceutical industry encounters some 
disadvantages, as the compound is volatile [14]. 
Nanotechnology can thus offer an efficient ap-
proach to minimize these limitations. Moreo-
ver, it can potentially improve the efficacy of 
traditional drug delivery and adjust the pharma-
cokinetics and administration, thereby reducing 
adverse effects [15, 16].  
Solid lipid nanoparticles (SLN) emerged in 
the 1990s as promising nanocarriers for cancer 
therapy. They offer several advantages, such as 
low toxicity [17-19], high bioavailability of 
drugs, and the capacity to load a range of chem-
ically different drugs. It enables the transport 
across physiological barriers, improves the de-
livery of drugs to the target cell, can escape 
mechanisms of resistance, and proves to be ef-
fective against breast, lung, colon, liver, and 
brain tumors [20, 21]. Besides, SLN is reported 
to be biocompatible and safe carriers for a range 
of administration routes, while their solid ma-
trix contributes to the controlled release of 
loaded drugs. Thus, SLN can be a promising na-
noplatform for the incorporation of antitumor 
drugs with, such as PA, with the aim of improv-
ing its bioavailability, efficiency, and biosafety 
profile, while reducing its volatility [22-24].  
In this work, we aimed at developing SLN for 
the loading of PA as an innovative, biocompat-
ible, and biosafe nanoparticle-based approach 
for chemotherapeutic treatment. Monoterpene 
release from SLN, physicochemical properties, 
bioavailability, cytotoxicity, and antitumor ef-
fect in a sarcoma 180 mice model have been 
studied. 
2. Materials and methods 
2.1. Materials 
Cetyl palmitate was donated as a gift from 
Croda (Campinas, Brazil); PA and Poloxamer® 
407 were purchased commercially from Sigma-
Aldrich (Taufkirchen, Germany). If not other-
wise stated, all other reagents were supplied 
from Sigma-Aldrich (St. Louis, Missouri, 
USA). Double-distilled water was used after fil-
tration in a Millipore system (home supplied). 
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2.2. SLN preparation 
SLN were developed by high-shear homoge-
nization [22]. Briefly, the aqueous phase con-
sisted of the aqueous solution, the surfactant 
Poloxamer®407 (0.0025 g/mL), and the oil 
phase consisted of cetyl palmitate dissolved in 
ethanolic solution (0.0125 g/mL, w/mL). Both 
phases were homogenized by magnetic stirring 
for 24 hours (Marte Científica, São Paulo, Bra-
zil), at room temperature (25ºC). After stirring, 
both phases were heated in a water bath at 70ºC, 
and the oil phase was poured into the aqueous 
phase and homogenized using Ultraturrax® 
(IKA T18, Staufen im Breisgau, Germany) at a 
speed of 22000 rpm for 5 minutes. The formu-
lation was cooled down in an ice bath and fil-
tered through a Millipore filter (Merck KGaA, 
Darmstadt, Germany) with a pore size of 0.45 
µm, followed by 0.22 µm. For the encapsulation 
of the PA, the same procedure was used by add-
ing the monoterpene to the oil phase before ho-
mogenization. 
2.3. Particle size, polydispersity index, 
and zeta potential 
The average size, polydispersity index, and 
zeta potential of SLN were determined by pho-
ton correlation spectroscopy (Malvern Zeta 
sizer, Nano Z-S; Malvern Instruments, Worces-
tershire, United Kingdom). The analyses were 
performed at an angle of 90 degrees at 25°C and 
a 633 mW He-Ne laser with a wavenumber of 
632.8 nm. An aliquot with a dilution factor of 
1: 100 was taken at half the height of the cuvette 
and measured in triplicate. 
2.4. Encapsulation efficiency (EE %) 
The formulations were centrifuged (DIK-
6750 Centrifugal Mixer, Saitama, Japan) at 
16000 rpm for 1 hour at room temperature. The 
drug quantification was performed by ultravio-
let spectrophotometry at 245 nm, using a UV 
FEMTO 800 XI (FEMTO Spectrophotometer, 
São Paulo, Brazil) against a validated calibra-
tion curve. The EE %) was calculated using the 







2.5. Thermal analysis 
The thermogravimetry (TG) analysis was per-
formed in a thermo-balance (Shimadzu TG-60, 
Kyoto, Japan) in the range of 25–500°C, under 
nitrogen atmosphere (N2), with a gas flow rate 
of 50 mL min−1, and a heating rate of 10°C 
min−1. Differential scanning calorimetry (DSC) 
curves (DSC 2010 TA Instruments, Mettler To-
ledo, Columbus, Ohio, United States) were 
scanned in the range 0–350°C, under a nitrogen 
atmosphere (N2), with a gas flow rate of 50 mL 
min−1, and a heating rate of 10°C min−1. The 
aluminum sample of both TG and DSC held 
contained 6.0 to 8.0 mg of sample [22]. 
2.6. Wide-angle X-ray diffraction (WAXD)  
The X-ray diffractograms of the samples were 
obtained on a diffractometer (Shimadzu XRD-
7000, Kyoto, Japan), operating in scanning 
mode with CUKα radiation (λ = 1.5418 Å), 
voltage 40 kV, current 30 mA, scanning speed 
(2θ) = 0.01 min-1, with an acquisition time of 5 
seconds for each step. The calibration of the 
scanning angle (2θ) was done with polycrystal-
line silicon. 
2.7. Transmission electronic microscopy 
Transmission electron microscopy images 
were obtained using a transmission electron mi-
croscope (TEM-MSC JEOL 210, Tokyo, Ja-
pan), electron diffraction analysis of the se-
lected area (SAED) of the SLN, and SLN-PA 
samples was performed using the microscope 
software. 
2.8. In vitro drug release  
The in vitro release study was performed us-
ing the dialysis method, adapted from Andrade 
et al. [26]. Precisely, 10 mL of the SLN-PA so-
lution was placed in the dialysis bag (5 cm long, 
25 mm wide, and 16 mm in diameter InLab, 
Brazil) and surrounded by 40 mL of phosphate 
buffer at 37 ± 1°C, pH 7.0 ± 0.4, under stirring 
at 200 rpm. These releasing processes were 
conducted over 8 hours, and 200 µL of the ali-
quots were collected and filtered at various time 
points (100, 200, 300, 400, and 500 min) with 
medium replacement to be quantified by UV-
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Vis spectrophotometry. The release kinetics 
was analyzed according to different mathemat-
ical models, namely, Baker and Lonsdale, 
Korsmeyer-Peppas, Hixon and Crowell, Higu-
chi, and First Order.  
2.9. Cell viability  
Cell viability was assessed by the colorimetric 
method using methyl-thiazolyl-tetrazolium 
(MTT). The L929 murine fibroblast cell line 
was provided by LGC Standards SLU, Barce-
lona, Spain. Cells were grown in cell culture 
bottles (75 cm3, 250 mL volume), using RPMI 
1640 and supplemented with 10% fetal bovine 
serum and 1% antibiotics (penicillin/streptomy-
cin) as media. This cell line was used as a model 
in testing of free PA, SLN, and SLN-PA at a 
concentration of 30 μg/mL each and based on 
the ISO 10993-5 [27]. L929 cells were seeded 
in 96-well culture plates (2 × 10⁴ cells/well), 
grown in Dulbecco’s modified Eagle’s medium 
containing NaHCO3 (1.2 g L−1), ampicillin 
(0.025 g L−1), streptomycin (0.1 g L−1) and sup-
plemented with 10 % FBS. After contact with 
PA, SLN, and SLN-PA, the cells were incu-
bated for 24 hours (37°C in a 5% CO2 atmos-
phere), centrifuged, and MTT (5 mg mL−1) was 
added. After 3 hours of incubation with MTT 
(37°C in a 5% CO2 atmosphere), the formazan 
product was dissolved in 80 μL dimethyl sul-
foxide (DMSO) for 10 minutes. Then the ab-
sorbance was measured using a microplate 
reader at 570 nm. The tests were performed in 
quadruplicate. 
2.10. Antitumor effect  
2.10.1. Animals  
The experimental protocol was submitted and 
approved by the Animal Care and Use Commit-
tee (CEUA) at Tiradentes University CEUA 
under registration number No. 021116R. Forty 
Swiss mice (female, weight varying between 25 
and 30 g) were obtained from the central bio-
therium of Tiradentes University, Brazil. The 
animals were housed and kept under a temper-
ature-controlled room (22–25ºC), with 12:12 
hour light-dark cycle and free access to food 
and water. Sarcoma 180 (S180) cells were ob-
tained from the Federal University of Sergipe. 
The donor animal was anesthetized via intra-
peritoneal and euthanized in a CO2 chamber. 
After, 0.5 mL of ascitic tumor cells were aspi-
rated from the animal’s abdominal cavity so 
that viable cells were selected using the trypan 
blue exclusion method [28]. 2 × 106 cells/0.5 
mL/mouse was inoculated into the recipient an-
imals, subcutaneously, in the animal’s left axil-
lary region [28-30]. After 24 hours of inocula-
tion, intraperitoneal (i.p.) treatments were 
started to assess the effect of drugs on tumor 
growth, one application a day for seven consec-
utive days. The animals were split into 4 groups 
(n=06) denominated empty SLN (vehicle), 
SLN-PA (100 mg kg−1 per day), SLN-PA (200 
mg kg−1 per day), and 5-FU-25 mg kg−1 per day 
(positive control). After 24 h the last day of 
treatment, the animals were euthanized by in-
duction in a CO2 chamber, and the tumors were 
removed.  
2.10.2. Toxicological evaluation - biochemi-
cal and immunological parameters  
For the quantification of the biochemical pa-
rameters (urea, creatinine, aspartate ami-
notransferase) AST, and alanine aminotransfer-
ase (ALT), the blood of the mice was subjected 
to centrifugation for 10 minutes at 3500 rpm to 
obtain plasma. Biochemical and hematological 
analysis was carried out using specific kits for 
the automatic biochemical analyzer Cobas Mira 
Plus™ and the automatic cellular hematology 
analyzer Animal Blood Counter Vet. Blood ex-
tensions were stained manually and analyzed 
using an optical microscope. 
2.10.3. Histopathological evaluation of or-
gans 
After weighing the spleen, liver, kidneys, and 
tumor, tissues were sectioned, fixed in buffered 
formalin (10% formaldehyde solution) for his-
topathological analysis. Briefly, samples went 
through a dehydration series of increasing 
amounts of alcohol (70 to 100%), diaphaniza-
tion in xylol, impregnation, and inclusion in 
paraffin, according to established protocols. In 
a semi-automatic rotary microtome (American 
Optical®), the tissue fragments embedded in 
paraffin were sectioned at a thickness of 3.0 μm 
and subsequently subjected to hematoxylin-eo-
sin staining, and then examined using an optical 
microscope.  
2.11. Statistical analysis 
The results are reported as the mean ± stand-
ard error of the mean, and for multiple compar-
isons of the data, analysis of variance was per-
formed (ANOVA), followed by the Student 
Newman Keuls or Dunnet post-test using the 
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GraphPad Prism version 7.0 program 
(GraphPad Software, San Diego, CA, USA). 
3. Results and Discussion 
Several drugs currently used in clinical prac-
tice exhibit high toxicity and lipophilicity, low 
bioavailability, and significant instability in bi-
ological systems [26]. Given these limitations, 
efforts are being put forward to improve tar-
geted delivery of drugs exploiting innovative 
techniques (e.g., micro/nanoencapsulation) to 
enhance their pharmacological effects while 
also ensuring safety for patients undergoing 
treatment. In this context, continuing the work 
of Cavendish et al. [22] and considering the an-
titumor effect of the PA described by Andrade 
et al. [28, 31], the present study aimed to de-
velop, characterize and evaluate the in vitro and 
in vivo activity of the SLN loading PA (SLN-
PA). 
The particle size of SLN was 489.95 ± 0.23 
nm, and the SLN-PA was 254.77 ± 8.10 nm. 
The size is a critical parameter to ensure the 
quality (and safety) of nanoparticles for nano-
medical applications [17, 32]. Nanoparticles of 
around 200 nm in size can easily leak through 
the tissue fenestrae into the tumor and be re-
tained [33], resulting in enhanced permeability 
and retention (EPR) effect. This EPR effect is 
now becoming the gold-standard in cancer 
treatment for which nanoparticles are instru-
mental for targeted drug delivery. The polydis-
persity index of SLN and SLN-PA werewas17 
± 0.001 and 0.350 ± 0.016, respectively. Values 
below 0.3 indicate homogeneity of the formu-
lation, which reveals a high stability of SLN 
[34]. The zeta potential, as an indirect measure 
of the surface electrical charge of the particles, 
results from the interaction of the charges of 
molecules present in the SLN with the sur-
rounding and can be used to predict the nano-
particles risk aggregation under storage. The 
zeta potential can be attributed to the surfac-
tants used to stabilize the particles, while the 
ideal zeta potential values are reported to be 
around |30 mV|[35]. The zeta potential results 
obtained for SLN and SLN-PA were 
−17.0 ± 0.50 and −14.7 ± 1.21 mV, respec-
tively. The slightly negative values are at-
tributed to the concentration of the non-ionic 
surfactant Polaxamer® 407, resulting in the re-
duction of the absolute values of the surface 
electrical charge. Although reducing the zeta 
potential, these hydrophilic non-ionic polymers 
(e.g., poloxamers) also contribute to reduce the 
risk of particle aggregation as they are placed 
onto the surface of the particles promoting ste-
reochemical hindrance. In a study by Sioli 
Montoto et al. [36], the developed SLN showed 
zeta potential values between −2.4 and 
−6.3 mV, which could compromise the electro-
static stability of SLN. However, the presence 
of the non-ionic surfactant (Pluronic®F68) pro-
moted the long-term stability from the hydro-
philic hindrance surrounding the particles. 
Both the lipid crystallinity and drug lipo-
philicity influenced the EE of PA in SLN. EE 
of SLN-PA was 84.6% ± 0.1016. From the pre-
formulation studies, such high values were ex-
pected [22]. The mixture of the lipid (cetyl pal-
mitate) with the PA decreased in crystallinity, 
making the nanoparticles more amorphous and 
offering room to accommodate more drug mol-
ecules, thus increasing the matrix capacity to 
load PA. The decreased crystallinity of lipid 
matrices, when loaded with monoterpenes, has 
also been reported by other authors [34, 37, 38].  
The in vitro kinetics study was conducted to 
understand the release mechanism of PA from 
SLN (Supplementary material S1). Approxi-
mately 30% of the PA showed a modified re-
lease over the course of 8 hours without any 
burst effects with a prolonged kinetic profile 
over the course of the experiment. According to 
Oehlke et al. [16], the PA lipophilicity favors 
solubilization in the lipid matrix of the SLN, 
prolonging the release time. In a study by Da 
Rosa et al. [39], approximately 50% of loaded 
thymol and carvacrol took about 72 hours to be 
released from zein nanoparticles, demonstrat-
ing an extended release of monoterpenes. Ziel-
inska et al. [9] also reported the modified re-
lease profile of several monoterpenes (i.e., al-
pha-pinene, citral, geraniol, and limonene) 
from glycerol monostearate composed SLN. 
Mathematical modeling has been used to de-
scribe the release mechanism of PA from SLN, 
applying Baker and Lonsdale, Korsmeyer-Pep-
pas, Hixon and Crowell, Higuchi, Square Root, 
First Order, and Weibull. For each fitting 
model, R2 value has been determined for both 
profiles (free PA and SLN-PA), and parameters 
corresponding to the obtained release data are 
shown in Table 1. Both release profiles could 
be better described by the Korsmeyer-Peppas 
fitting model as the R2 value was found to be a 
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perfect linear correlation kinetics for PA before 
and after its loading into lipid nanoparticles. 
Korsmeyer-Peppas model is generally used to 
describe the release of a drug from a matrix 
when the mechanism is not well known or when 
one or more types of phenomena are involved 
[24]. This model is described by the power-law 
equation𝑀! 𝑀" 	= 𝑘#⁄ 𝑡$, in which	𝑀!	trans-
lates the cumulative amount of drug being re-
leased at the time t, 𝑀" is the cumulative amount 
of drug released at infinite time, 𝑘# is a constant 
governed by the physicochemical properties of 
the matrix, and n is the diffusional release expo-
nent. It is this latter, i.e., n value, that describes 
the release mechanism of the drug. When 
n=0.5, the release is governed by the Fickian dif-
fusion, when 0.5 < n < 1.0, a non-Fickian diffu-
sion is observed. When the drug release becomes 
time-independent, it becomes a zero-order re-
lease in a Case II transport, as seen in spherical 
particles. When n approaches 1.0, a typical re-
lease following a non-Fickian transport is ob-
served. In the case of SLN, the type of solid lipid 
selected as matrix material plays a critical role 
in the release kinetics profile, as the lipid is re-
sponsible for the solubility and entrapment of 
the drug within the solid matrix of SLN [40]. 
Cetyl palmitate is known to recrystallize in a 
metastable polymorphic which controls the 
drug outlet from the SLN. However, SLN ma-
trix erodes, its porosity increases so that the 
drug can be released [26]. 
Table 1. In vitro release coefficient obtained from the different mathematical fitting models for free 
PA and SLN-PA profiles (Release profile depicted in Supplementary Material, S1). 
Mathematical model Free PA SLN-PA 
Baker and Lonsdale 0.8146 0.8776 
Korsmeyer-Peppas 1.0000 1.0000 
Hixon and Crowell 0.9998 0.9989 
Higuchi, Square Root 0.8191 0.8895 
First Order 0.9997 0.9976 
PA = perillyl alcohol; SLN-PA = solid lipid nanoparticles incorporated with perillyl alcohol. 
 
Thermal analysis is a tool used to analyze pol-
ymorphic transitions and changes in lipids’ 
physical and chemical properties as a function 
of temperature. In particular, the DSC method 
is the most frequently used in the investigation 
of the physical state of dispersed particles, de-
tecting melting and endothermic transfor-
mations, which are typical upon heating (or the 
absence of these endotherms under cooling). 
DSC gives important information about the en-
trapped drug within SLN [41, 42]. Fusion can 
be associated with the dissolution of the drug in 
a lipid matrix or with the fusion of the complex 
formed between lipid and drug [43, 44]. The 
main use of TG comprises the evaluation of the 
thermal stability of drugs and carriers through 
thermal-induced weight loss of a sample as a 
function of temperature. 
The TG/DTG curves of the PA revealed a loss 
of mass (∆m1 91.43%.), with an onset at 126ºC 
and its end at approximately 177ºC, attributed to 
the decomposition of the monoterpene. Supple-
mentary S2 shows the TG/DTG curves for PA, 
SLN, and SLN-PA. TG/DTG curves of the SLN 
showed a mass loss event between 220.10 and 
326.68°C (∆m1 91.43%), attributed to the degra-
dation of the lipid. Similar mass loss events for 
the wax cetyl palmitate have been reported else-
where [22, 45, 46]. The SLN-PA showed a mass 
loss event between 244.74 and 326.48 ºC related 
to the loss of mass of ∆m1 34.5%, following one 
thermal event attributed to the decomposition. 
The monoterpene loading into SLN changed the 
thermal properties of the lipid, indicating the 
presence of the drug within the SLN matrix. 
The thermal analysis of SLN is instrumental 
in estimating the stability of the lipid matrix 
[47]. DSC profiles of the PA, SLN, and SLN-
PA are shown in Supplementary S3. The DSC 
curve of PA showed an endothermic event be-
tween 121.99 and 146.99°C (ΔH = -
456.88 Jg−1) attributed to the volatilization and 
decomposition of the monoterpene. The DSC 
profile curve of SLN exhibited one endother-
mic peak valued between 48.36 and 60.75°C 
(ΔH = -113.39 Jg−1), which corresponds to the 
melting of the solid lipid (cetyl palmitate), as 
confirmed by the literature [22, 45, 46]. The 
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loading of PA into the SLN resulted in some 
modifications of the thermal behavior. The 
SLN-PA thermogram showed an endothermic 
peak with two maxima. The first one is visible 
between 46.22 and 54.32ºC (ΔH −26.37 Jg−1) 
and the second between 54.32 to 60.79°C 
(ΔH = −3.82 Jg−1). The endothermic peak was 
absent in the range of volatilization of PA, 
which can be explained considering the disso-
lution of PA in the molten lipid during encap-
sulation [37]. The formulation showed a melt-
ing peak higher than 45°C. This characteristic 
ensures the solid structure of particles at room 
temperature (~25°C). 
The morphology of SLN and SLN-PA was 
visualized by TEM (Supplementary S4). Figure 
S4A shows the spherical and smooth shape of 
PA-free SLN. The loading of PA into SLN also 
resulted in SLN of spherical shape and smooth 
surface (S4B), in which black points are visible 
with higher resolution, suggesting the effective 
encapsulation of PA into the lipid matrix. TEM 
results are in agreement with the recorded mean 
diameters by dynamic light scattering, also re-
ported by other authors [48, 49]. 
The cytotoxicity profile of SLN (with and 
without PA) was evaluated against L929 mu-
rine fibroblast cells. As shown in Figure 1, all 
tested samples (i.e., control group, bulk PA, 
SLN, and SLN-PA) showed cellular viability of 
above 70%, i.e., 99.57 ± 0.30 %, 
94.6 ± 5.51 %, 99.14 ± 1.03 %, 99.6 ± 0.37%, 
respectively. Free PA was also shown to be 
non-cytotoxic against normal fibroblasts; cell 
viability was greater than 99%. Besides, iso-
lated PA showed a similar result compared to 
SLN-PA, which also did not induce any toxic 
effect. The results indicate the safety and bio-
compatibility of formulations and free PA for 
eukaryotic cells. Any cytotoxic effect of nano-
particles in vitro results from their adhesion to 
the cell membrane, their internalization, and 
degradation inside the cells [50, 51]. The cell 
susceptibility to a specific product is dependent 
on the type of cell [52], and is governed by the 
physicochemical properties of the surface and 
matrix of the particles. While enough evidence 
on their preclinical safety based on the biocom-
patibility and biodegradability of lipids has 
been gathered, the main critical issue is the type 
of surfactant surrounded by the particles on the 
cell viability in vitro [17]. SLN were obtained 
from cetyl palmitate surrounded by a non-ionic 
surfactant (Pluronic®F68). Cetyl palmitate is a 
naturally occurring vegetable wax derived from 
cetyl alcohol and palmitic acid, with a hydro-
philic-lipophilic balance value of 10. Pluronic 
is a polyoxyethylene-polyoxypropylene block 
copolymer suitable for cell culture. Both sub-
stances are generally recognized as safe, while 
literature has demonstrated in vitro biocompat-
ibility of such systems. Cytotoxic activity of PA 
against tumor cell lines of ovarian adenocarci-
noma (OVCAR-8), colon carcinoma (HCT-
116), and glioblastoma (SF295) has already 
been shown by us [31]. The effect of the PA 
loading on the viability of L929 fibroblast cells 
was evaluated (Figure 1).  
 
Figure 1. Effect of perillyl alcohol (PA), solid lipid nanoparticles (SLN), and solid lipid nanoparticles-perillyl alcohol 
(SLN-PA) on the viability of human L929 fibroblasts determined by MTT assay after 24 hours of incubation. The control 
group was treated with the vehicle used to dilute the drug (DMSO 5%). The data correspond to the mean ± standard error of 
the mean of four independent experiments. 
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Cell viability remained above 99% for all 
tested samples in comparison to control, con-
firming the lack of cytotoxicity of PA, SLN, 
and SLN-PA on mouse L929 fibroblasts.  
Figure 2 shows the values of the tumor inhi-
bition rate and tumor mass of the treated ani-
mals and their respective controls. After intra-
peritoneal administration, SLN-PA inhibited 
tumor growth in 51.76 % (0.95 ± 0.07 g) and 
54.49 % (0.90 ± 0.08 g) in doses of 100 and 
200 mg/kg/day, respectively. 5-FU (positive 
control, PC) in the dose of 25 mg/kg/day inhib-
ited tumor growth in 91.07 % (0.14 g ± 0.12 g). 
These results show that the SLN-PA at doses of 
100 and 200 mg/kg/day have Antitumor effect 
in the sarcoma 180 mice model.  
 
Figure 2. In vivo antitumor activity of solid lipid nanoparticles incorporated with perillyl alcohol (SLN-PA) in doses of 100 
and 200 mg/kg/day (intraperitoneal) for seven consecutive days. The vehicle-treated group was treated with DMSO 5% and 
positive control treated with 5-Fluorouracil (5-FU 25 mg/kg/day). Values correspond to the mean ± s  of 10 animals/group 
analyzed by ANOVA followed by Student Newman Keuls post-test. * p < 0.05 compared to the negative control group. 
Andrade et al. [28] evaluated the in vivo An-
titumor effect of isolated PA (intraperitoneally) 
in the sarcoma 180 model, demonstrating tumor 
growth inhibition of 35.3 % and 45.4 % for the 
doses of 100 and 200 mg/kg/day, respectively. 
Comparing these latter with the results obtained 
in the present work, an increase in tumor 
growth inhibition was observed for SLN-PA 
when comparing both PA doses. SLN-PA in-
creased the Antitumor effect of the drug against 
sarcoma 180 without the need to increase dos-
age. Other antineoplastics as camptothecin, 
doxorubicin, methotrexate, mitoxantrone, oxal-
iplatin, and tamoxifen are examples of chemo-
therapeutics that use SLN to prolong the release 
of the drug, increase the amount of drug in the 
bloodstream, facilitate the cellular uptake of the 
incorporated drugs by the modulation of pas-
sive, active, cotransport mechanisms and can 
overcome biological barriers which result in 
improving cytotoxic activity or inhibition rate 
of tumor growth in vivo [53]. 
Most antineoplastic drugs currently used are 
cytotoxic to tumor cells, but they also have non-
specific action as they reach healthy cells, lead-
ing to undesirable side effects. All antineo-
plastic drugs cause gastrointestinal changes and 
weight loss in a murine model [54]. The first 
parameter to be analyzed is, therefore, the vari-
ation in body mass. The results demonstrate 
that the groups of animals treated with SLN-PA 
in both doses show a reduction in body mass; 
however, less than the 5-FU antineoplastic (Ta-
ble 2). Despite the different administration 
routes, these results corroborate with those ob-
tained from human clinical trials, which 
demonstrated that patients using oral PA might 
experience nausea, vomiting, fatigue, lack of 
appetite, and consequently reduced body mass 
[55]. Based on these effects, oral PA did not ad-
vance to phase 3 clinical trials and, therefore, 
has not entered clinical practice for cancer treat-
ment [11].
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Table 2. Toxicological parameters of the evaluation of perillyl alcohol 
Parameters 
Treatments (mg/kg/day) 
Vehicle  SLN-PA 5-FU 
- 100 200 25 
Body weight (g) 1.10 ± 0.27 -0.88 ± 0.34+ -0.73 ± 0.29*  -2.40 ± 0.34* 
Liver (g/100g body weight) 4.86 ± 0.08 4.99 ± 0.19  4.90 ± 0.22 4.63 ± 0.12 
Spleen (g/100g body weight) 0.49 ± 0.02 0.44 ± 0.04  0.47 ± 0.08 0.36 ± 0.04* 
Kidney (g/100g body weight) 1.09 ± 0.08 1.10 ± 0.04 1.11 ± 0.1 1.11 ± 0.06 
AST (U/L) 268 ± 22.5 293.3 ± 20.9 294.1 ± 16.2 186.1 ± 18.3 
ALT (U/L) 56.4 ± 3.8 70.8 ± 7.6 66.4 ± 3.9 61.5 ± 4.7 
Urea (mg/dL) 41.6 ± 4.5 42.3 ± 2.2 36.1 ± 2.2 35 ± 4.6 
Creatinine (mg/dL) 1.7 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.8 ± 0.1 
Total leukocytes (×103 cells/µL) 9.9 ± 0.7 7.5 ± 0.3*# 6.8 ± 0.5*#  2.2 ± 0.6*  
Neutrophil (%) 39.6 ± 3.5  23.3 ± 3.0* 22.9 ± 1.6* 12.4 ± 2.5* 
Lymphocyte (%) 56 ± 3.8 73 ± 2.7* 74 ±1.2* 88.6 ± 2.2* 
Monocyte (%) 1.5 ± 0.2 1.8 ± 0.4 1.7 ± 0.3  0.5 ± 0.3 
AST = aspartate aminotransferase; ALT = alanine aminotransferase; SLN-PA = solid lipid nanoparticles incor-
porated with perillyl alcohol. Data are presented as mean values ± standard error of mean of 8 mice by group with 
sarcoma 180. 5-FU: 5-Fluorouracil used as the positive control intraperitoneally. *p < 0.05 when compared with 
the vehicle and #p < 0.05 when compared with 5-FU using one-way ANOVA and Tukey test for multiple com-
parisons.  
 
As renal and liver disorders are common out-
comes of chemotherapy, their functions were 
investigated by determining organ mass, bio-
chemical parameters (hepatic - AST and ALT, 
renal - urea and creatinine), and histopatholog-
ical section (Table 3, Figure 2 and 3) of animals 
treated with SLN-PA. None of these parameters 
showed significant changes, indicating the for-
mulation does not promote liver and kidney 
damage when used for 7 consecutive days on 
front sarcoma 180. These results corroborate 
with data obtained with derivatives of PA 
(perillaldehyde 8,9-epoxide and perillaldehyde 
1,2-epoxide) in animals with sarcoma 180, 
treated for 7 consecutive days intraperitoneally, 
where liver or kidney changes are not observed 
either [28, 31]. 
The immunological parameters evaluated in 
animals treated with SLN-PA were spleen 
mass, total leukocytes count, and differential 
count. Antineoplastic agents commonly cause 
changes in the immune system with variation in 
the mass of lymphoid organs (spleen), leukope-
nia, and changes in the ratio of lymphocytes and 
neutrophils in the differential count [56].  
In the animals treated with this formulation, a 
reduction in spleen mass, a reduction in the 
number of total leukocytes (leukopenia), and a 
significant change in the amounts of circulating 
lymphocytes and neutrophils was observed. 
These results suggest that the SLN-PA can 
cause immunosuppression. Upon microscopic 
examination, the livers of animals treated with 
SLN-PA 100 mg/kg and 200 mg/kg did not 
show any morphological changes (Figure 3A). 
The lobular-type architecture was observed, 
with thin-walled, equidistant terminal hepatic 
veins, portal spaces, regularly distributed and 
small, with a lax matrix comprising biliary vas-
cular tracts (bile ducts, portal vein branch, and 
branches of the hepatic artery without histolog-
ical particularities). In the portal spaces, normal 
hepatocytes were observed. Kidneys removed 
from the group treated with SLN-PA at doses of 
100 and 200 mg/kg showed normal morpholog-
ical standards (Figure 3B). 
Namely, the lobes were well defined and with 
medullary rays, represented by the medullary 
pyramid and cortical tissue covering their base 
and sides. 
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Figure 3. Histopathology of the experimental groups: (A, left panels) healthy tissue, (B, middle panels) and (C, right panels) 
of solid lipid nanoparticles incorporated with perillyl alcohol (SLN-PA) 100 mg/kg and 200 mg/kg, respectively. The tissue 
sections were stained with hematoxylin and eosin (H&E) and analyzed by optical microscopy (× 400), at 5 µm thickness. (a) 
Photomicrograph of the liver. The black arrows indicate normal hepatocytes and Kupffer cells. (b) Photomicrograph of the 
kidney. The black arrows indicate the Bowman space (thin arrows) and preserved proximal contorted tubules (thick arrows) 
common in all groups. (c) Photomicrograph of the spleen. The black arrows indicate the splenic trabeculae and normal splenic 
sinuses.
The analysis performed by optical micros-
copy showed conserved and well-distributed 
cortical and medullary regions. The glomeruli 
belonging to the animals of the transplanted 
control group SLN-PA (100 and 200 
mg/kg/day) were surrounded by a thin Bowman 
capsule, the Bowman space, and capillary tuft 
being sustained for delicate melange. 
The contorted proximal tubules, collecting tu-
bules, and Henle loops were supported by 
scarce fibroconjunctive tissue and covered by 
epithelium with variable height, from columnar 
to pavement, typical of renal tissue. The medul-
lary region also showed collecting tubules di-
rected towards the papillae, outlined by tall 
cells, with clearly visible cytoplasm. 
The same was observed in the spleen micros-
copy without histopathological changes. Solid, 
lobulated configuration, with thin septa of fi-
brocollagenic tissues scarce intratumoral 
stroma, a proliferation of immature cells, small 
or medium-sized, irregularly shaped, some of 
which are bizarre, multinucleated and giant. 
They exhibit eosinophilic cytoplasms, with 
clear borders, hyperchromatic or vesicular nu-
clei with coarse chromatin, oval or pleo-
morphic, with prominent nucleoli (Figure 3C). 
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Solid lipid nanoparticles have been used to improve the effectiveness of volatile and lipophilic active 
ingredients by increasing the pharmacological activity at the site of action, the half-life, as well as min-
imizing systemic variability. The loading of PA in the SLN improved the safety profile of the drug and 
prolonged its release. SLN containing PA demonstrated an antitumor effect in vivo in a sarcoma 180 
tumor model with few changes in toxicological parameters, which demonstrates the potential applica-
bility of SLN-PA for cancer therapy. Due to the versatility of SLN, these are promising nanocarriers 
for chemotherapy as they show high bioavailability, low toxicity, effective transport between physio-
logical barriers, thus determining the supply of drugs to target cells. SLN represents a promising system 
for the incorporation of active ingredients with antitumor effects, such as PA. 
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Figure S1. In vitro release profile of free PA and SLN-PA.  




Figure S2. TG/DTG curves of PA, SLN and SLN-PA. TG/DTG = thermogravimetry/derivative thermogravimetry;  
PA = perillyl alcohol; SLN = solid lipid nanoparticles; SLN-PA = solid lipid nanoparticles incorporated with perillyl alco-
hol. 
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Figure S3. DSC curves of PA, SLN and SLN-PA.  
DSC = differential scanning calorimetry; PA = perillyl alcohol; SLN = solid lipid nanoparticles; SLN-PA = solid lipid 
nanoparticles incorporated with perillyl alcohol. 
 
Figure S4. Transmission electron microscopy analysis of SLN (A, bar = 200 nm) and of SLN-PA (B, bar = 60 nm).  
SLN = solid lipid nanoparticles; SLN-PA = solid lipid nanoparticles incorporated with perillyl alcohol. 
